- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Comparing Tbo-Filgrastim With Filgrastim During Neutrophil Engraftment
A study comparing the efficacy of tbo-filgrastim with filgrastim when used to mobilize peripheral blood stem cells or to accelerate engraftment after autologous stem cell transplantation found no clinically meaningful differences, plus tbo-filgrastim saved money.
A study comparing the efficacy of tbo-filgrastim with filgrastim when used to mobilize peripheral blood stem cells or to accelerate engraftment after autologous stem cell transplantation found that there were no clinically meaningful differences.
The paper, by researchers from the Texas Transplant Institute, was published in Biology of Blood and Marrow Transplantation.
The researchers studied patients diagnosed with lymphoma or plasma cell disorders who were undergoing granulocyte colon-stimulating factor mobilization. The primary outcome was total collected CD34(+) cells/kg.
Secondary engraftment endpoints of the study were time to neutrophil and events of febrile neutropenia. There were no statistically significant differences in these endpoints.
A total of 185 patients were included in the analysis, and the researchers found that patients receiving filgrastim collected a median of 5.56 × 10(6) CD34(+) cells/kg, compared with a median of 5.85 × 10(6) CD34(+) cells/kg in the tbo-filgrastim group.
Not only were there no statistically meaningful differences in the endpoints, such as events of febrile neutropenia and length of stay, but tbo-filgrastim was associated with savings of $1406 per patient based on the average wholesale price of the treatment.
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More
